Fastest
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →https://www.patsnap.com/resources/blog/rd-blog/viscoelastic-hemostasis-testing-patent-landscape/ · Patsnap · data cut-off 2026-07-31 · downloaded from the live page
Patent Landscape · Coagulation TestingViscoelastic Hemostasis Testing Patents: Who Holds the Claims
- 29.9% concentration. The top 5 assignees account for 678 of 2,266 records in scope — a field with a clear head, not a flat field of equal competitors.
- Filing has plateaued, not collapsed. Complete-year filings moved from 79 in 2021 to 78 in 2024, roughly flat over that span; treat 2025–2026 counts as still filling in.
- G01N testing claims sit well behind A61K therapeutic claims. Only 29.1% of records carry a G01N material-analysis class versus 56.9% for A61K, pointing to device and assay claim space that is comparatively less crowded.
2,266
Published Records
30%
Top-5 Share of All Records
-1%
Filing Growth 2021→2024
US
Leading Jurisdiction
Filing growth compares 2021 (79 records) with 2024 (78) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 2,266 records in scope (CR5), not by the ranked leaders only.
Published byPatsnap Research··6 min readSourced from Patsnap Eureka
Overview
What this landscape covers
Viscoelastic hemostasis testing spans thromboelastography and rotational thromboelastometry devices, the reagents and cartridges that run them, and the transfusion algorithms built on their output. This landscape draws on 2,266 patent records published between 2015 and mid-2026, filtered to documents that combine viscoelastic testing terms with clot-firmness, transfusion-algorithm, cartridge, or operator-dependence language. Families, not raw document counts, are the fairer unit for judging real filing activity, since a single family can generate several publications across jurisdictions.
The composition of IPC classes shows a field anchored in medicinal preparations and therapeutic claims (A61K, A61P) but with a substantial testing-and-measurement layer (G01N, C12Q, B01L) underneath it — the hardware, cartridge, and algorithmic side of the technology rather than the drug side.
Filing activity and technology mix, 2015–2026
Source: Patsnap Eureka. Assignee ranking and totals. Derived from a Patsnap search on Viscoelastic Hemostasis Testing covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
The Numbers
Filing trends and technology composition
Publication counts by year and by IPC subclass, drawn directly from the 2,266 records in scope. Recent years are understated because publication trails filing by roughly 18 months.
Filing trend: rising into 2022, then levelling
Filings climbed from 130 in 2017 to a peak of 137 in 2022. Comparing the last two complete years, 2021 (79) to 2024 (78) shows filing volume essentially flat, a -1% change — read this as a plateau after growth, not a decline, since 2025 and 2026 have not finished publishing.
Technology composition by IPC subclass
A61K medicinal preparations lead at 56.9% of all 2,266 records, with A61P therapeutic-activity claims close behind at 33.3%. The testing and apparatus side is smaller: G01N material analysis and testing sits at 29.1%, C12Q enzyme/DNA measurement at 7.5%, and B01L lab apparatus at 5.8% — each record can carry multiple classes, so these shares add up past 100%.
Shares are the percentage of the 2,266 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Source: Patsnap Eureka. Filing trend and technology composition. Derived from a Patsnap search on Viscoelastic Hemostasis Testing covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.
Go deeper on Viscoelastic Hemostasis Testing with Eureka
This page is one run against one query. Ask Eureka your own question about viscoelastic hemostasis testing and every answer comes back with the patent numbers behind it.
Try EurekaKey Patents
The most-cited records in this space
Representative Filing
Coagulation and fibrinolysis assays (US20200208194A1)
UNIVERSITY OF COLORADO
Coagulation and fibrinolysis assays and related compositions, systems, methods, and kits are provided. In some embodiments, the assay utilizes one or more biological molecules combined with a blood or blood-derived patient sample, measuring properties associated with coagulation and/or fibrinolysis. The biological molecules may shorten assay duration or enhance sensitivity relative to conventional assays, and may allow pathological coagulation and fibrinolysis phenotypes to be identified.Filed by University of Colorado, published 2020-07-02.
Highest-cited patents in scope
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US4148216A | Apparatus for determining the viscous behavior of a liquid during coagulation thereof | 138 |
| 2 | US20100154520A1 | Cartridge device for a measuring system for measuring viscoelastic characteristics of a sample liquid, a corr… | 127 |
| 3 | WO2008051291A2 | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof | 98 |
| 4 | US8668926B1 | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof | 97 |
| 5 | WO2013083858A1 | Compounds suitable for treatment of haemophilia | 92 |
| 6 | US20090022806A1 | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses ther… | 86 |
| 7 | US20090130645A1 | Method for assessing the fibrinogen contribution in coagulation | 83 |
| 8 | WO2016028810A1 | Anti-CD40 antibodies and uses thereof | 81 |
| 9 | US20140294821A1 | Factor viii chimeric and hybrid polypeptides, and methods of use thereof | 79 |
| 10 | WO2013009627A2 | Factor viii chimeric and hybrid polypeptides, and methods of use thereof | 73 |
Citation counts favour older filings that have had more time to accumulate references — read them as a signal of influence within this corpus, not of current relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Source: Patsnap Eureka. Citation counts and representative records. Derived from a Patsnap search on Viscoelastic Hemostasis Testing covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Run it yourself
Put your own technology through the same analysis
Where to run it
For builders
MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →Insights
What the data signals for R&D and IP strategy
Three patterns worth acting on before scoping new filings or freedom-to-operate work in this space.
Concentration
29.9%
of 2,266 records held by top 5
The field has a defined head, not a flat distribution
Top 5 assignees combine for 678 of 2,266 records (29.9%), and the top 10 extend that to 995 records (43.9%). New entrants are filing into a space where a handful of assignees already hold dense position around core device and formulation claims.
Based on the full 100-company ranking returned for this dataset.
Filing momentum
79 → 78
records, 2021 to 2024 (-1%)
Growth has flattened after a 2022 peak
Filings peaked at 137 in 2022. Comparing the last two complete years, 2021 to 2024 shows a roughly flat -1% change, suggesting the core inventive territory mapped so far is largely claimed rather than still expanding rapidly.
2025–2026 figures will rise as publication catches up with filing.
Claim distribution
29.1%
of records carry a G01N class
Testing-hardware claims trail therapeutic claims
A61K medicinal-preparation claims cover 56.9% of records, more than double the 29.1% carrying G01N material-analysis and testing classes. Cartridge, sensor, and algorithmic claim space is comparatively thinner than the formulation side of the field.
Classes overlap; shares are computed against the full 2,266-record base.
Eureka AI Agent
Looking for what nobody has claimed yet?
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to viscoelastic hemostasis testing, with the prior art for and against each one.
Source: Patsnap Eureka. Co-assignee relationships and derived observations. Derived from a Patsnap search on Viscoelastic Hemostasis Testing covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Players
Who holds position, and where the gaps sit
The ranked leaders in this dataset cover 100 companies; a small group of pharmaceutical and device assignees hold the strongest position, but several documented branches remain under-claimed.
Leader
250
records
A single assignee well ahead of the field
The top-ranked assignee holds 250 records, more than three times the fifth-place holder at 80 and five times the tenth-place holder at 50 — a steep drop-off rather than a gradual one.
Counts are by patent family within the assignee ranking.
Co-filing
82
shared records, strongest pair
Co-assignee pairs cluster around corporate affiliates
The strongest co-assignee pair shares 82 records, and a university pair shares 31 — a mix of corporate parent-subsidiary filing and academic collaboration among the 10 documented co-assignee pairs.
Ten co-assignee pairs are documented in this dataset.
Momentum
-94% YoY
one assignee's latest-year change
Recent-year activity has thinned across former leaders
Several previously active assignees show 0 or 1 record in the latest year, and one shows a -94% year-on-year drop from a low base — consistent with the plateau seen in the overall filing trend rather than a broad retreat from the field.
Latest-year counts are partial; publication lag applies.
Recent-year filing momentum by assignee
| Assignee | Recent year | YoY |
|---|---|---|
| C A Casyso GmbH | 1 | — |
| Bioverativ Therapeutics Inc | 1 | — |
| Velico Medical Inc | 1 | -94% |
| Baxter International Inc | 0 | — |
| Baxalta GmbH | 0 | — |
| Novo Nordisk Health Care AG | 0 | — |
| Bioverativ Therapeutics Inc | 0 | — |
| Baxalta Inc | 0 | — |
Source: Patsnap Eureka. Assignee-level momentum. Derived from a Patsnap search on Viscoelastic Hemostasis Testing covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
What's Next
Where to take this analysis
The dataset points to specific next steps depending on whether you are scoping freedom-to-operate, planning new filings, or tracking competitors.
Run a freedom-to-operate check on cartridge claims
With G01N testing claims at 29.1% of records versus 56.9% for A61K formulations, cartridge and device claims are comparatively less crowded but still held by named leaders — worth checking before committing to a specific mechanical design.
Explore claim scope in EurekaTrack the leader's recent-year filing pace
The top-ranked assignee's 250-record position was built over years of filing; recent-year momentum data shows where that pace has slowed, which can signal where new claim territory is opening up.
Monitor assignee activity in EurekaMap the under-claimed branches against your own pipeline
Operator-independent detection and transfusion decision-support show thinner density in this dataset than the core assay space — a useful starting point for scoping a first claim.
Build a white-space map in EurekaSource: Patsnap Eureka. Forward-looking reading of the same dataset. Derived from a Patsnap search on Viscoelastic Hemostasis Testing covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
FAQ
Common questions about this landscape
The dataset's ranked leader holds 250 records, well ahead of the fifth-place assignee at 80 and the tenth-place assignee at 50. The top 5 assignees combined account for 678 of 2,266 records in scope, or 29.9%, and the top 10 extend that to 43.9%. This is a field with a clear concentration at the top rather than an even spread across many small filers.
Filing peaked at 137 records in 2022 after climbing from 130 in 2017. Comparing the last two complete years, 2021 (79 records) to 2024 (78 records), volume is essentially flat, a -1% change, rather than clearly growing or shrinking. Figures for 2025 and 2026 will rise as publication catches up with filing, since publication typically lags filing by around 18 months.
Both terms are captured together in this search, since the underlying technology — measuring clot firmness over time from a blood sample — is claimed similarly across device, reagent, and algorithm patents regardless of which trade name a filer uses. The technology composition data shows claims split across therapeutic formulation classes (A61K, A61P) and testing/apparatus classes (G01N, B01L, C12Q), reflecting that both device makers and pharmaceutical companies file in this space.
The clearest gap sits in the testing-hardware layer: only 29.1% of the 2,266 records carry a G01N material-analysis class, well below the 56.9% carrying A61K medicinal-preparation classes. Sub-areas such as operator-independent clot-firmness detection, cartridge miniaturisation, and automated transfusion-algorithm decision support show comparatively thin claim density relative to the core formulation and device space, making them worth a closer freedom-to-operate look before filing.
Citation counts accumulate over time, so a patent published in the 1970s or 1980s, such as the most-cited record in this dataset, has had decades longer to be cited than a 2023 filing. This means high citation counts signal historical influence on the field's foundational claims, not that the underlying technology remains the most commercially relevant today. Recent, less-cited patents can still cover the claim space that matters most for current product development.
Answers are grounded in the same dataset. Derived from a Patsnap search on Viscoelastic Hemostasis Testing covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Research Viscoelastic Hemostasis Testing in depth with Eureka
Go past this page: query the whole viscoelastic hemostasis testing corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company's registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.